7MM 糖尿病數位治療市場 - 2025 年至 2033 年

7MM 糖尿病數位療法市場規模在 2024 年達到 9.6109 億美元，預計到 2033 年將達到 25.7846 億美元，在 2025-2033 年預測期內的複合年成長率為 11.7%。

糖尿病的數位療法是指基於證據的、軟體驅動的干涉措施，旨在透過數位平台管理和治療糖尿病。這些治療方法使用行動應用程式、穿戴式裝置和基於雲端的系統等先進技術來提供個人化的即時治療策略和行為介入。目標是利用數據驅動的洞察力來改善糖尿病管理、提高患者治療效果並預防併發症。

糖尿病的數位療法使用來自穿戴式裝置（例如，連續血糖監測儀）和使用者輸入（例如，飲食和運動）的即時資料來提供個人化建議。這有助於患者對藥物、飲食和體力活動做出明智的決定，從而最佳化他們的血糖水平和整體健康狀況。

市場動態：

促進因素與約束因素

不斷進步的技術正在推動 7MM 糖尿病數位療法市場的成長

人工智慧（AI）功能正在融入數位療法，以即時分析大量患者資料（例如血糖水平、活動、飲食），以了解糖尿病和相關慢性病。這使得制定高度個人化的治療計劃以適應個人的特定需求成為可能，從而改善血糖控制和長期健康結果。因此，主要市場參與者正專注於糖尿病數位治療中的先進人工智慧功能。

例如，2025 年 2 月，家庭護理領域的領導者、Owens & Minor 家族旗下的 Byram Healthcare 推出了由 Welldoc App 提供支援的個人化數位健康計劃 ByramConnect。該程式利用 Welldoc App 先進的人工智慧功能，分析會員六個健康維度的資料，幫助最佳化 1 型或 2 型糖尿病患者以及高血壓、體重管理和心血管風險等相關慢性病患者的治療效果，為 Byram 會員提供可與其服務提供者和護理團隊共享的可行見解和報告。

穿戴式設備，例如連續血糖監測儀（CGM），可即時且連續地追蹤血糖值。這有助於更好地決策並及時干預，以防止低血糖或高血糖。與數位治療平台整合的 CGM 系統為患者和醫療保健提供者提供持續的回饋。這種整合提高了管理效率，減少了緊急干預，並提高了患者的生活品質。這些先進的 CGM 系統採用了小​​型感測器和智慧發射器等技術，成為市場成長的主要趨勢。

例如，2024 年 10 月，Ascensia Diabetes Care 為美國糖尿病患者推出了 Eversense 365 連續血糖監測 (CGM) 系統，這是世界上唯一一款為期一年的 CGM。 Eversense 365 由 Senseonics Holdings, Inc. 開發，是唯一一款提供一年準確監測且干擾最小的 CGM，僅需一個 CGM 即可做出自信的決策、長期的安心並提高生活品質。 Senseonics 的 CGM 系統 Eversense 365 包括一個完全插入皮下的小型感測器，可與感測器上佩戴的智慧發射器進行通訊。血糖資料每 5 分鐘自動發送到用戶智慧型手機上的行動應用程式。

數據隱私和安​​全問題阻礙了糖尿病市場數位療法的發展

數位治療平台收集大量敏感的個人健康資料。如果患者不確定這些數據的儲存安全性或誰可以存取這些數據，他們通常不願意共享這些資料。這種猶豫可能會延遲或限制數位健康解決方案的採用。數位治療平台必須遵守嚴格的法規，例如美國的《健康保險流通與責任法案》（HIPAA）、歐盟的《一般資料保護規範》（GDPR）以及其他地區的類似法規。處理患者資料的複雜合規性要求可能會成為市場成長的重大障礙，尤其是對於較小的公司或新創公司而言。

數位治療領域缺乏資料保護和安全的通用標準。不同公司、應用程式和設備之間不一致的做法可能會留下漏洞，從而暴露患者資訊。網路安全風險是一個主要問題，尤其是隨著數位健康平台和穿戴式裝置的互聯程度越來越高。針對健康資料的駭客可能會危害患者的安全和對數位治療的信任。

例如，根據《HIPAA雜誌》報導，2023 年 8 月，有 2,300 萬份醫療記錄被洩露。在過去的 12 個月中，平均每月有 9,989,003 份醫療記錄被洩露。截至 2024 年 8 月 31 日的一年中，已發生 491 起涉及 500 筆或更多記錄的資料外洩事件，已知外洩記錄至少有 58,668,002 則。 2024 年的平均洩漏記錄規模目前為 119,487 筆記錄，中位洩漏記錄規模為 4,109 筆記錄。

目錄

第1章：市場介紹和範圍

• 報告目標
• 報告範圍和定義
• 報告範圍

第 2 章：高階主管見解與關鍵要點

• 市場亮點和戰略要點
• 主要趨勢和未來預測
• 按產品類型分類
• 按應用程式截取的程式碼片段
• 最終用戶的程式碼片段
• 國家摘要

第 3 章：動態

• 影響因素
  • 驅動程式
    • 糖尿病盛行率上升
    • 不斷進步的技術
  • 限制
    • 資料隱私和安全問題
    • 監管挑戰
  • 機會
    • 糖尿病數位治療中的人工智慧
  • 影響分析

第4章：戰略洞察與產業展望

• 市場領導者和先驅者
  • 新興先鋒和傑出參與者
  • 擁有最大銷售品牌的成熟領導者
  • 擁有成熟產品的市場領導者
• 新興創業公司和關鍵創新者
• CXO 觀點
• 最新進展與突破
• 案例研究/正在進行的研究
• 監管和報銷情況
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
• 波特五力分析
• 供應鏈分析
• 專利分析
• SWOT 分析
• 未滿足的需求和差距
• 市場進入和擴張的推薦策略
• 情境分析：最佳情況、基本情況和最壞情況預測
• 定價分析和價格動態

第 5 章：糖尿病數位治療市場（依產品類型）

• 軟體解決方案
  • 行動應用程式
  • 基於 Web 的解決方案
• 硬體解決方案
  • 穿戴式裝置
  • 連續血糖監測儀
  • 其他

第 6 章：糖尿病數位治療市場（按應用）

• 1 型糖尿病
• 2 型糖尿病
• 糖尿病前期

第 7 章：糖尿病數位治療市場（以最終用戶分類）

• 醫院
• 專科診所
• 家庭護理設置
• 其他

第 8 章：糖尿病數位治療市場（按國家/地區分類）

• 美國
  • 關鍵國家特定動態
• 法國
• 德國
• 義大利
• 西班牙
• 英國
• 日本

第9章：競爭格局與市場定位

• 競爭概況和主要市場參與者
• 市佔率分析與定位矩陣
• 策略夥伴關係、併購
• 產品組合和創新的關鍵發展
• 公司基準化分析

第10章：公司簡介

• Welldoc, Inc.
• 公司概況
• 產品組合
  • 產品描述
  • 產品關鍵績效指標 (KPI)
  • 歷史和預測產品銷售量
  • 產品銷售量
• 財務概覽
  • 公司收入
  • 地區收入佔有率
  • 收入預測
• 關鍵進展
  • 合併與收購
  • 關鍵產品開發活動
  • 監管部門批准等
• SWOT 分析
• Omada Health Inc.
• Glooko, Inc.
• Azumio Inc.
• Abbott Laboratories
• mySugr GmbH
• Dexcom, Inc.
• Health2Sync
• iHealth Labs Inc.
• Medtronic plc

第 11 章：假設與研究方法

• 資料收集方法
• 數據三角測量
• 預測技術
• 數據驗證和確認

第 12 章：附錄

The 7MM digital therapeutics for diabetes market size reached US$ 961.09 million in 2024 and is expected to reach US$ 2,578.46 million by 2033, growing at a CAGR of 11.7% during the forecast period 2025-2033.

Digital therapeutics for diabetes refer to evidence-based, software-driven interventions designed to manage and treat diabetes through digital platforms. These therapeutics use advanced technologies like mobile apps, wearable devices, and cloud-based systems to deliver personalized, real-time treatment strategies and behavioral interventions. The goal is to improve diabetes management, enhance patient outcomes, and prevent complications by leveraging data-driven insights.

Digital therapeutics for diabetes use real-time data from wearables (e.g., continuous glucose monitors) and user inputs (e.g., diet and exercise) to provide personalized recommendations. This helps patients make informed decisions about medication, diet, and physical activity, optimizing their blood glucose levels and overall health.

Market Dynamics: Drivers & Restraints

Rising technological advancements are driving the 7MM digital therapeutics for diabetes market growth

Artificial intelligence (AI) capabilities are being integrated into digital therapeutics to analyze vast amounts of patient data (e.g., glucose levels, activity, diet) in real-time for diabetes and associated chronic conditions. This enables the creation of highly personalized treatment plans that adapt to the individual's specific needs, improving glycemic control and long-term health outcomes. Thus, the key market players are focusing on the advanced artificial intelligence capabilities in their diabetes digital therapeutics.

For instance, in February 2025, Byram Healthcare, a leader in home-based care and part of the Owens & Minor family, launched ByramConnect, a personalized digital health program powered by the Welldoc App. Using the Welldoc App's advanced artificial intelligence capabilities, the program analyzes member data across six dimensions of health to help optimize outcomes for people with type 1 or type 2 diabetes and associated chronic conditions such as hypertension, weight management, and cardiovascular risk, providing Byram members with actionable insights and reports that can be shared with their providers and care teams.

Wearable devices, such as Continuous Glucose Monitors (CGMs), provide real-time, continuous tracking of glucose levels. This allows for better decision-making and timely interventions to prevent hypoglycemia or hyperglycemia. CGM systems that integrate with digital therapeutics platforms, provide continuous feedback to both patients and healthcare providers. This integration improves management efficiency, reduces emergency interventions, and enhances patient quality of life. These advanced CGM systems with advancements such as small sensors and smart transmitters becoming a key trend for market growth.

For instance, in October 2024, Ascensia Diabetes Care, launched the Eversense 365 continuous glucose monitoring (CGM) system, the world's only One-year CGM, for people with diabetes in the U.S. Developed by Senseonics Holdings, Inc., Eversense 365 is the only CGM that provides one year of accurate monitoring with minimal disruptions, enabling confident decisions, long-term peace of mind and enhanced quality of life with just one CGM. Senseonics' CGM system Eversense 365 includes a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

Data privacy and security concerns hamper the growth of digital therapeutics for the diabetes market

Digital therapeutics platforms collect vast amounts of sensitive personal health data. Patients are often reluctant to share this data if they are unsure about how securely it is stored or who can access it. This hesitation can delay or limit the adoption of digital health solutions. Digital therapeutics platforms must comply with stringent regulations like the Health Insurance Portability and Accountability Act (HIPAA) in the U.S., the General Data Protection Regulation (GDPR) in the EU, and similar regulations in other regions. The complex compliance requirements for handling patient data can be a significant barrier to market growth, especially for smaller companies or startups.

There is a lack of universal standards for data protection and security in the digital therapeutics sector. Inconsistent practices across different companies, apps, and devices can leave vulnerabilities that may expose patient information. Cybersecurity risks are a major concern, especially as digital health platforms and wearable devices become more interconnected. Hackers targeting health data can compromise patient safety and trust in digital therapeutics.

For instance, according to the HIPAA Journal, in August 2023, 23 million breached healthcare records are reported. Over the past 12 months, an average of 9,989,003 healthcare records were breached each month. In the year to August 31, 2024, there have been 491 data breaches of 500 or more records, and at least 58,668,002 records are known to have been breached. The average breach size in 2024 is currently 119,487 records, and the median breach size is 4,109 records.

Segment Analysis

The 7MM digital therapeutics for diabetes market is segmented based on product type, application, end-user, and country.

Product Type:

The software solutions in the product type segment are expected to dominate the 7MM digital therapeutics for diabetes market with the highest market share

Software solutions are highly scalable and can be accessed by a wide range of patients, regardless of location. They can be used on mobile phones, tablets, and computers, making them accessible to a larger population, including those in remote areas. Software solutions allow for the customization of diabetes care based on real-time data, such as blood glucose levels, exercise routines, and dietary habits.

The major market players are continuously focusing on software solutions, which further accelerates the market growth. For instance, in November 2024, Medtronic received U.S. Food and Drug Administration (FDA) clearance for its new InPen smartphone app and announced the launch of its new Smart MDI system. Smart MDI was designed to provide real-time insights to users on multiple daily injection (MDI) therapy. It includes the InPen smart insulin pen, the InPen app, and Medtronic's disposable, all-in-one Simplera continuous glucose monitor (CGM), which received U.S. Food and Drug Administration approval

Software solutions enable continuous tracking of vital metrics like blood glucose levels, insulin usage and physical activity. This constant monitoring allows for immediate interventions and reduces the need for frequent in-person visits, thus enhancing patient engagement and improving long-term outcomes.

Competitive Landscape

The major players in the 7MM digital therapeutics for diabetes market include Welldoc, Inc., Omada Health Inc., Glooko, Inc., Azumio Inc., Abbott Laboratories, mySugr GmbH, Dexcom, Inc., Health2Sync, iHealth Labs Inc. and Medtronic plc and among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The 7MM digital therapeutics for diabetes market report delivers a detailed analysis with 39 key tables, more than 26 visually impactful figures and 158 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

• 1.1. Objectives of the Report
• 1.2. Report Coverage & Definitions
• 1.3. Report Scope

2. Executive Insights and Key Takeaways

• 2.1. Market Highlights and Strategic Takeaways
• 2.2. Key Trends and Future Projections
• 2.3. Snippet by Product Type
• 2.4. Snippet by Application
• 2.5. Snippet by End-User
• 2.6. Snippet by Country

3. Dynamics

• 3.1. Impacting Factors
  • 3.1.1. Drivers
    • 3.1.1.1. Rising Prevalence of Diabetes
    • 3.1.1.2. Rising Technological Advancements
  • 3.1.2. Restraints
    • 3.1.2.1. Data Privacy and Security Concerns
    • 3.1.2.2. Regulatory Challenges
  • 3.1.3. Opportunity
    • 3.1.3.1. Artificial Intelligence in Diabetes Digital Therapeutics
  • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

• 4.1. Market Leaders and Pioneers
  • 4.1.1. Emerging Pioneers and Prominent Players
  • 4.1.2. Established leaders with the largest selling Brand
  • 4.1.3. Market leaders with established Product
• 4.2. Emerging Startups and Key Innovators
• 4.3. CXO Perspectives
• 4.4. Latest Developments and Breakthroughs
• 4.5. Case Studies/Ongoing Research
• 4.6. Regulatory and Reimbursement Landscape
  • 4.6.1. US
  • 4.6.2. France
  • 4.6.3. Germany
  • 4.6.4. Italy
  • 4.6.5. Spain
  • 4.6.6. UK
  • 4.6.7. Japan
• 4.7. Porter's Five Force Analysis
• 4.8. Supply Chain Analysis
• 4.9. Patent Analysis
• 4.10. SWOT Analysis
• 4.11. Unmet Needs and Gaps
• 4.12. Recommended Strategies for Market Entry and Expansion
• 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 4.14. Pricing Analysis and Price Dynamics

5. Digital Therapeutics for Diabetes Market, By Product Type

• 5.1. Introduction
  • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 5.1.2. Market Attractiveness Index, By Product Type
• 5.2. Software Solutions*
  • 5.2.1. Introduction
  • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.2.3. Mobile Apps
  • 5.2.4. Web-Based Solutions
• 5.3. Hardware Solutions
  • 5.3.1. Wearable Devices
  • 5.3.2. Continuous Glucose Monitors
  • 5.3.3. Others

6. Digital Therapeutics for Diabetes Market, By Application

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 6.1.2. Market Attractiveness Index, By Application
• 6.2. Type-1 Diabetes*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Type-2 Diabetes
• 6.4. Pre-Diabetes

7. Digital Therapeutics for Diabetes Market, By End-User

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 7.1.2. Market Attractiveness Index, By End-User
• 7.2. Hospitals*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Specialty Clinics
• 7.4. Homecare Settings
• 7.5. Others

8. Digital Therapeutics for Diabetes Market, By Country

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  • 8.1.2. Market Attractiveness Index, By Country
• 8.2. US*
  • 8.2.1. Introduction
  • 8.2.2. Key Country-Specific Dynamics
  • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
• 8.3. France
• 8.4. Germany
• 8.5. Italy
• 8.6. Spain
• 8.7. UK
• 8.8. Japan

9. Competitive Landscape and Market Positioning

• 9.1. Competitive Overview and Key Market Players
• 9.2. Market Share Analysis and Positioning Matrix
• 9.3. Strategic Partnerships, Mergers & Acquisitions
• 9.4. Key Developments in Product Portfolios and Innovations
• 9.5. Company Benchmarking

10. Company Profiles

• 10.1. Welldoc, Inc.*
  • 10.1.1. Company Overview
  • 10.1.2. Product Portfolio
    • 10.1.2.1. Product Description
    • 10.1.2.2. Product Key Performance Indicators (KPIs)
    • 10.1.2.3. Historic and Forecasted Product Sales
    • 10.1.2.4. Product Sales Volume
  • 10.1.3. Financial Overview
    • 10.1.3.1. Company Revenue
    • 10.1.3.2. Geographical Revenue Shares
    • 10.1.3.3. Revenue Forecasts
  • 10.1.4. Key Developments
    • 10.1.4.1. Mergers & Acquisitions
    • 10.1.4.2. Key Product Development Activities
    • 10.1.4.3. Regulatory Approvals, etc.
  • 10.1.5. SWOT Analysis
• 10.2. Omada Health Inc.
• 10.3. Glooko, Inc.
• 10.4. Azumio Inc.
• 10.5. Abbott Laboratories
• 10.6. mySugr GmbH
• 10.7. Dexcom, Inc.
• 10.8. Health2Sync
• 10.9. iHealth Labs Inc.
• 10.10. Medtronic plc

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

• 11.1. Data Collection Methods
• 11.2. Data Triangulation
• 11.3. Forecasting Techniques
• 11.4. Data Verification and Validation

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us